CO2022015891A2 - Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres - Google Patents
Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceresInfo
- Publication number
- CO2022015891A2 CO2022015891A2 CONC2022/0015891A CO2022015891A CO2022015891A2 CO 2022015891 A2 CO2022015891 A2 CO 2022015891A2 CO 2022015891 A CO2022015891 A CO 2022015891A CO 2022015891 A2 CO2022015891 A2 CO 2022015891A2
- Authority
- CO
- Colombia
- Prior art keywords
- mirdametinib
- lifirafenib
- cancers
- treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente descripción se refiere a métodos para tratar cánceres que comprenden la administración conjunta de mirdametinib o una forma de sal farmacéuticamente aceptable de este y lifirafenib o una forma de sal farmacéuticamente aceptable de este a un paciente que lo necesita. También se describen composiciones farmacéuticas de mirdametinib o una forma de sal farmacéuticamente aceptable de este y lifirafenib o una forma de sal farmacéuticamente aceptable de este para uso en tal tratamiento del cáncer, así como usos de estos compuestos para la elaboración de medicamentos para el tratamiento de cánceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063005153P | 2020-04-03 | 2020-04-03 | |
PCT/US2021/025551 WO2021202981A1 (en) | 2020-04-03 | 2021-04-02 | Co-administration of mirdametinib and lifirafenib for use in treating cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022015891A2 true CO2022015891A2 (es) | 2023-05-08 |
Family
ID=75674969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0015891A CO2022015891A2 (es) | 2020-04-03 | 2022-11-03 | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230128315A1 (es) |
EP (1) | EP4125842B1 (es) |
JP (1) | JP2023521036A (es) |
KR (1) | KR20230048476A (es) |
CN (1) | CN116194095A (es) |
AU (1) | AU2021246141A1 (es) |
BR (1) | BR112022019914A2 (es) |
CA (1) | CA3174223A1 (es) |
CL (1) | CL2022002682A1 (es) |
CO (1) | CO2022015891A2 (es) |
DK (1) | DK4125842T3 (es) |
IL (1) | IL296878A (es) |
MX (1) | MX2022012351A (es) |
PE (1) | PE20231211A1 (es) |
TW (1) | TW202207910A (es) |
WO (1) | WO2021202981A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11806321B2 (en) * | 2022-03-17 | 2023-11-07 | Springworks Therapeutics, Inc. | Non-linear dosing of mirdametinib |
US20230293464A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
WO2024081948A1 (en) * | 2022-10-14 | 2024-04-18 | Springworks Therapeutics, Inc. | Combination for use in treating cancers |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6147246B2 (ja) * | 2011-04-01 | 2017-06-14 | ジェネンテック, インコーポレイテッド | Akt及びmek阻害剤化合物の組み合わせ、及び使用方法 |
WO2019113345A1 (en) * | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
EP3560516A1 (en) * | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
-
2021
- 2021-04-02 CA CA3174223A patent/CA3174223A1/en active Pending
- 2021-04-02 KR KR1020227038490A patent/KR20230048476A/ko unknown
- 2021-04-02 US US17/995,002 patent/US20230128315A1/en active Pending
- 2021-04-02 WO PCT/US2021/025551 patent/WO2021202981A1/en unknown
- 2021-04-02 MX MX2022012351A patent/MX2022012351A/es unknown
- 2021-04-02 JP JP2022560245A patent/JP2023521036A/ja active Pending
- 2021-04-02 EP EP21721706.6A patent/EP4125842B1/en active Active
- 2021-04-02 BR BR112022019914A patent/BR112022019914A2/pt unknown
- 2021-04-02 AU AU2021246141A patent/AU2021246141A1/en active Pending
- 2021-04-02 CN CN202180036587.XA patent/CN116194095A/zh active Pending
- 2021-04-02 IL IL296878A patent/IL296878A/en unknown
- 2021-04-02 DK DK21721706.6T patent/DK4125842T3/da active
- 2021-04-02 TW TW110112271A patent/TW202207910A/zh unknown
- 2021-04-02 PE PE2022002181A patent/PE20231211A1/es unknown
-
2022
- 2022-09-30 CL CL2022002682A patent/CL2022002682A1/es unknown
- 2022-11-03 CO CONC2022/0015891A patent/CO2022015891A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4125842A1 (en) | 2023-02-08 |
JP2023521036A (ja) | 2023-05-23 |
TW202207910A (zh) | 2022-03-01 |
BR112022019914A2 (pt) | 2022-12-13 |
AU2021246141A1 (en) | 2022-12-01 |
IL296878A (en) | 2022-12-01 |
CA3174223A1 (en) | 2021-10-07 |
WO2021202981A1 (en) | 2021-10-07 |
EP4125842B1 (en) | 2024-06-05 |
CN116194095A (zh) | 2023-05-30 |
DK4125842T3 (da) | 2024-07-22 |
CL2022002682A1 (es) | 2023-06-16 |
US20230128315A1 (en) | 2023-04-27 |
KR20230048476A (ko) | 2023-04-11 |
MX2022012351A (es) | 2023-03-13 |
PE20231211A1 (es) | 2023-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
CO2018004206A2 (es) | Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d” | |
AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
UY31800A (es) | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb | |
AR078588A1 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
ECSP23096498A (es) | Restos de administración terapéutica novedosos y usos de estos | |
RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
MX2018003685A (es) | Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento. | |
CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
AR085132A1 (es) | Composiciones farmaceuticas para el tratamiento de glioma maligno | |
CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
AR108792A1 (es) | Composiciones que comprenden timolol |